SELLAS Life Sciences (SLS) Non Operating Income (2010 - 2026)
SELLAS Life Sciences (SLS) reported Non Operating Income of $845000.0 for Q1 2026, up 238.0% year-over-year from $250000.0 in Q1 2025, and up 41.54% quarter-over-quarter from $597000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Non Operating Income (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 15 years of Non Operating Income data on file, last reported at $845000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at $845000.0, up 238.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.0 million (up 149.81% YoY), and the FY2025 annual result was $1.4 million, up 123.26% from the prior year.
- Non Operating Income grew to $845000.0 in Q1 2026 per SLS's latest filing, from $597000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $845000.0 in Q1 2026 and troughed at $41000.0 in Q4 2023.
- A 5-year average of $254687.5 and a median of $209500.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income slumped 87.38% in 2023, then soared 341.46% in 2024.
- A 5-year view of Non Operating Income shows it stood at $325000.0 in 2022, then tumbled by 87.38% to $41000.0 in 2023, then soared by 341.46% to $181000.0 in 2024, then soared by 229.83% to $597000.0 in 2025, then soared by 41.54% to $845000.0 in 2026.
- Business Quant data shows SLS's Non Operating Income at $845000.0 in Q1 2026, $597000.0 in Q4 2025, and $292000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | SELLAS Life Sciences | 1.39 Bn | 1.39 Bn | - | 845,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 845,000.00 |
| Dec 31, 2025 | 597,000.00 |
| Sep 30, 2025 | 292,000.00 |
| Jun 30, 2025 | 272,000.00 |
| Mar 31, 2025 | 250,000.00 |
| Dec 31, 2024 | 181,000.00 |
| Sep 30, 2024 | 221,000.00 |
| Jun 30, 2024 | 151,000.00 |
| Mar 31, 2024 | 79,000.00 |
| Dec 31, 2023 | 41,000.00 |
| Sep 30, 2023 | 94,000.00 |
| Jun 30, 2023 | 210,000.00 |
| Mar 31, 2023 | 184,000.00 |
| Dec 31, 2022 | 325,000.00 |
| Sep 30, 2022 | 124,000.00 |
| Jun 30, 2022 | 209,000.00 |
| Dec 31, 2019 | -7.50 Mn |
| Sep 30, 2019 | -4.20 Mn |
| Jun 30, 2019 | -3.13 Mn |
| Dec 31, 2018 | -14.86 Mn |